


WHO AMR Products Data Analysis

1 Distribution of product type

Antibiotics :- 357

Non-traditional :- 259




2 #of products in each R&D phase

Phase I :- 284

Phase II :- 173

Phase III :- 132

Preregistration :- 27




3 Route_effectiveness

Distribution of products by route of administration and R&D phase :

- Most products taken through

IV or Oral were in phase I


-IV was included in all of phases



4 Efficacy counts


Activity against priority pathogens across R&D :

-Phase I has the highest positive activity




5 NCE status

All of the products were new chemical entities




5 Different levels of pathogen activity within each pathogen name :

Pathogens activity : critical priority were less than other priority



6 Antibacterial class distribution :

The majority of the classes are bacteriophage



Phase I



Distribution of AMR products in phase I

-Most cases & products were administrated intravenously.

Effect of phase I in IV pathogens

-TRL1068 :- highest activity against priority pathogens across phase I products

-Highest frequency of products name of IV admirative have activity against Enterobaterales & critical priority pathogens



Phase III

Distribution of AMR products in phase III

Effect of phase I in IV pathogens

Also most of them were IV less oral, not absorbed

